The weekly litigation news digest is live. Subscribe now

IP Verse

Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes - EP3152234

The patent EP3152234 was granted to Cellvax on Jun 26, 2024. The application was filed on Jun 5, 2015 under application number EP15732846A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3152234

CELLVAX
Application Number
EP15732846A
Filing Date
Jun 5, 2015
Status
Patent Maintained As Amended
May 24, 2024
Publication Date
Jun 26, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
HOFFMANN EITLEApr 8, 2021HOFFMANN EITLEWITHDRAWN

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0173494
DESCRIPTIONEP1586325
DESCRIPTIONUS5882877
DESCRIPTIONWO9514785
DESCRIPTIONWO9622378
DESCRIPTIONWO9845322
INTERNATIONAL-SEARCH-REPORTWO2010084999
INTERNATIONAL-SEARCH-REPORTWO2012177788
OPPOSITIONUS8329660
OPPOSITIONWO2010084999
OPPOSITIONWO2014144600
OPPOSITIONWO2016073299
OPPOSITIONWO2021139682
OTHERUS8329660
OTHERWO2010084999

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents